vs
艾伯维（ABBV）与Wellgistics Health, Inc.（WGRX）财务数据对比。点击上方公司名可切换其他公司
艾伯维的季度营收约是Wellgistics Health, Inc.的9947.0倍（$16.6B vs $1.7M）。艾伯维净利率更高（10.9% vs -1667.2%，领先1678.1%）
艾伯维是一家总部位于美国伊利诺伊州北芝加哥的制药企业，专注于研发、生产覆盖多种疾病领域的治疗药物，致力于为全球各地患者提供安全有效的临床解决方案，在全球医药行业拥有较高的知名度与影响力。
Wellgistics Health, Inc.是一家总部位于美国的医疗服务企业，主营处方药物、非处方药品及医疗用品的分销业务，服务对象包括零售药房、长期护理机构及各类独立医疗服务提供者。
ABBV vs WGRX — 直观对比
营收规模更大
ABBV
是对方的9947.0倍
$1.7M
净利率更高
ABBV
高出1678.1%
-1667.2%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $16.6B | $1.7M |
| 净利润 | $1.8B | $-27.9M |
| 毛利率 | 72.6% | -470.2% |
| 营业利润率 | 27.3% | -1517.5% |
| 净利率 | 10.9% | -1667.2% |
| 营收同比 | 10.0% | — |
| 净利润同比 | 8354.5% | — |
| 每股收益（稀释后） | $1.02 | $-0.24 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ABBVWGRX
| Q4 25 | $16.6B | $1.7M | ||
| Q3 25 | $15.8B | $3.0M | ||
| Q2 25 | $15.4B | $7.8M | ||
| Q1 25 | $13.3B | $10.9M | ||
| Q4 24 | $15.1B | — | ||
| Q3 24 | $14.5B | — | ||
| Q2 24 | $14.5B | — | ||
| Q1 24 | $12.3B | — |
净利润ABBVWGRX
| Q4 25 | $1.8B | $-27.9M | ||
| Q3 25 | $186.0M | $-34.3M | ||
| Q2 25 | $938.0M | $-6.7M | ||
| Q1 25 | $1.3B | $-32.4M | ||
| Q4 24 | $-22.0M | — | ||
| Q3 24 | $1.6B | — | ||
| Q2 24 | $1.4B | — | ||
| Q1 24 | $1.4B | — |
毛利率ABBVWGRX
| Q4 25 | 72.6% | -470.2% | ||
| Q3 25 | 66.4% | 7.7% | ||
| Q2 25 | 71.8% | 6.5% | ||
| Q1 25 | 70.0% | 6.4% | ||
| Q4 24 | 70.9% | — | ||
| Q3 24 | 70.9% | — | ||
| Q2 24 | 70.9% | — | ||
| Q1 24 | 66.7% | — |
营业利润率ABBVWGRX
| Q4 25 | 27.3% | -1517.5% | ||
| Q3 25 | 12.1% | -1047.1% | ||
| Q2 25 | 31.7% | -70.6% | ||
| Q1 25 | 28.0% | -288.6% | ||
| Q4 24 | -9.9% | — | ||
| Q3 24 | 26.5% | — | ||
| Q2 24 | 27.6% | — | ||
| Q1 24 | 22.7% | — |
净利率ABBVWGRX
| Q4 25 | 10.9% | -1667.2% | ||
| Q3 25 | 1.2% | -1139.0% | ||
| Q2 25 | 6.1% | -85.6% | ||
| Q1 25 | 9.6% | -298.5% | ||
| Q4 24 | -0.1% | — | ||
| Q3 24 | 10.8% | — | ||
| Q2 24 | 9.5% | — | ||
| Q1 24 | 11.1% | — |
每股收益（稀释后）ABBVWGRX
| Q4 25 | $1.02 | $-0.24 | ||
| Q3 25 | $0.10 | $-0.46 | ||
| Q2 25 | $0.52 | $-0.11 | ||
| Q1 25 | $0.72 | $-0.62 | ||
| Q4 24 | $-0.03 | — | ||
| Q3 24 | $0.88 | — | ||
| Q2 24 | $0.77 | — | ||
| Q1 24 | $0.77 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $5.3B | $42.6K |
| 总债务越低越好 | $58.9B | $23.5M |
| 股东权益账面价值 | $-3.3B | $-12.4M |
| 总资产 | $134.0B | $30.5M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ABBVWGRX
| Q4 25 | $5.3B | $42.6K | ||
| Q3 25 | $5.7B | $4.2M | ||
| Q2 25 | $6.5B | $419.9K | ||
| Q1 25 | $5.2B | $2.5M | ||
| Q4 24 | $5.6B | — | ||
| Q3 24 | $7.3B | — | ||
| Q2 24 | $13.2B | — | ||
| Q1 24 | $18.1B | — |
总债务ABBVWGRX
| Q4 25 | $58.9B | $23.5M | ||
| Q3 25 | $63.0B | $24.8M | ||
| Q2 25 | $63.0B | $23.3M | ||
| Q1 25 | $64.5B | $24.1M | ||
| Q4 24 | $60.3B | — | ||
| Q3 24 | $58.5B | — | ||
| Q2 24 | $58.0B | — | ||
| Q1 24 | $63.8B | — |
股东权益ABBVWGRX
| Q4 25 | $-3.3B | $-12.4M | ||
| Q3 25 | $-2.6B | $6.8M | ||
| Q2 25 | $-183.0M | $905.3K | ||
| Q1 25 | $1.4B | $4.5M | ||
| Q4 24 | $3.3B | — | ||
| Q3 24 | $6.0B | — | ||
| Q2 24 | $6.8B | — | ||
| Q1 24 | $8.0B | — |
总资产ABBVWGRX
| Q4 25 | $134.0B | $30.5M | ||
| Q3 25 | $133.9B | $52.8M | ||
| Q2 25 | $137.2B | $54.2M | ||
| Q1 25 | $136.2B | $58.1M | ||
| Q4 24 | $135.2B | — | ||
| Q3 24 | $143.4B | — | ||
| Q2 24 | $141.9B | — | ||
| Q1 24 | $148.9B | — |
负债/权益比ABBVWGRX
| Q4 25 | — | — | ||
| Q3 25 | — | 3.66× | ||
| Q2 25 | — | 25.72× | ||
| Q1 25 | 45.44× | 5.39× | ||
| Q4 24 | 18.15× | — | ||
| Q3 24 | 9.70× | — | ||
| Q2 24 | 8.56× | — | ||
| Q1 24 | 7.97× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $5.2B | $-6.3M |
| 自由现金流经营现金流 - 资本支出 | $4.9B | — |
| 自由现金流率自由现金流/营收 | 29.4% | — |
| 资本支出强度资本支出/营收 | 2.0% | — |
| 现金转化率经营现金流/净利润 | 2.87× | — |
| 过去12个月自由现金流最近4个季度 | $17.8B | — |
8季度趋势，按日历期对齐
经营现金流ABBVWGRX
| Q4 25 | $5.2B | $-6.3M | ||
| Q3 25 | $7.0B | $-1.1M | ||
| Q2 25 | $5.2B | $-2.1M | ||
| Q1 25 | $1.6B | $-1.3M | ||
| Q4 24 | $7.0B | — | ||
| Q3 24 | $5.4B | — | ||
| Q2 24 | $2.3B | — | ||
| Q1 24 | $4.0B | — |
自由现金流ABBVWGRX
| Q4 25 | $4.9B | — | ||
| Q3 25 | $6.6B | — | ||
| Q2 25 | $4.9B | — | ||
| Q1 25 | $1.4B | — | ||
| Q4 24 | $6.8B | — | ||
| Q3 24 | $5.2B | — | ||
| Q2 24 | $2.0B | — | ||
| Q1 24 | $3.8B | — |
自由现金流率ABBVWGRX
| Q4 25 | 29.4% | — | ||
| Q3 25 | 42.1% | — | ||
| Q2 25 | 31.7% | — | ||
| Q1 25 | 10.5% | — | ||
| Q4 24 | 44.7% | — | ||
| Q3 24 | 35.9% | — | ||
| Q2 24 | 14.0% | — | ||
| Q1 24 | 31.3% | — |
资本支出强度ABBVWGRX
| Q4 25 | 2.0% | — | ||
| Q3 25 | 2.4% | — | ||
| Q2 25 | 1.7% | — | ||
| Q1 25 | 1.8% | — | ||
| Q4 24 | 1.9% | — | ||
| Q3 24 | 1.7% | — | ||
| Q2 24 | 1.7% | — | ||
| Q1 24 | 1.6% | — |
现金转化率ABBVWGRX
| Q4 25 | 2.87× | — | ||
| Q3 25 | 37.76× | — | ||
| Q2 25 | 5.49× | — | ||
| Q1 25 | 1.27× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 3.49× | — | ||
| Q2 24 | 1.66× | — | ||
| Q1 24 | 2.95× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
